ATE266616T1 - Retinoid antagonisten und ihre verwendung - Google Patents
Retinoid antagonisten und ihre verwendungInfo
- Publication number
- ATE266616T1 ATE266616T1 AT99911748T AT99911748T ATE266616T1 AT E266616 T1 ATE266616 T1 AT E266616T1 AT 99911748 T AT99911748 T AT 99911748T AT 99911748 T AT99911748 T AT 99911748T AT E266616 T1 ATE266616 T1 AT E266616T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutically acceptable
- treatment
- dotted bond
- retinoid antagonists
- alkyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 150000004492 retinoid derivatives Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical class [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 230000001855 preneoplastic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/47—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1999/001467 WO2000053562A1 (en) | 1999-03-08 | 1999-03-08 | Retinoid antagonists and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE266616T1 true ATE266616T1 (de) | 2004-05-15 |
Family
ID=8167235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99911748T ATE266616T1 (de) | 1999-03-08 | 1999-03-08 | Retinoid antagonisten und ihre verwendung |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1161410B1 (de) |
| JP (1) | JP3752423B2 (de) |
| KR (1) | KR20010113037A (de) |
| CN (1) | CN1337931A (de) |
| AT (1) | ATE266616T1 (de) |
| AU (1) | AU762492B2 (de) |
| BR (1) | BR9917205A (de) |
| CA (1) | CA2366186C (de) |
| DE (1) | DE69917332T2 (de) |
| DK (1) | DK1161410T3 (de) |
| ES (1) | ES2221371T3 (de) |
| MX (1) | MXPA01009027A (de) |
| TR (1) | TR200102587T2 (de) |
| WO (1) | WO2000053562A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147224A (en) * | 1998-10-01 | 2000-11-14 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
| AU6941200A (en) | 1999-08-27 | 2001-03-26 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators |
| CZ2002711A3 (cs) | 1999-08-27 | 2003-11-12 | Ligand Pharmaceuticals Incorporated | Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CA2383565A1 (en) * | 1999-09-14 | 2001-03-22 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
| US6313168B1 (en) * | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| WO2001068135A2 (en) * | 2000-03-14 | 2001-09-20 | The University Of Western Ontario | Compositions and methods for affecting osteogenesis |
| AU2002255732B2 (en) * | 2001-03-14 | 2006-03-09 | Eli Lilly And Company | Fluorinated trienes and their use as RXR modulators |
| US20030170724A1 (en) | 2002-03-08 | 2003-09-11 | Anderson David C. | Methods of identifying target polypeptides |
| GB0308335D0 (en) | 2003-04-10 | 2003-05-14 | Novartis Ag | Organic compounds |
| EP1621191A1 (de) * | 2004-07-29 | 2006-02-01 | Werner Bollag | Behandlung von Entzündungserkrankungen mit RXR-Antagonisten |
| US20090016991A1 (en) * | 2004-07-29 | 2009-01-15 | Werner Bollag | Rxr Antagonist Treatment Against Multiple Sclerosis |
| JP2007070281A (ja) * | 2005-09-06 | 2007-03-22 | Matsumoto Shika Univ | レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤 |
| EP1940378A1 (de) * | 2005-10-25 | 2008-07-09 | Werner Bollag | Rxr-agonisten und antagonisten, allein oder in kombination mit ppar-liganden, bei der behandlung von metabolischen und kardiovaskulären erkrankungen |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| CN110105210B (zh) * | 2019-05-17 | 2021-08-03 | 山东省肿瘤防治研究院（山东省肿瘤医院） | 百里酚衍生物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719041B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| MX9704878A (es) * | 1994-12-30 | 1997-11-29 | Ligand Pharm Inc | Nuevos compuestos retinoides trienoicos y metodos de uso. |
| US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
-
1999
- 1999-03-08 CN CN99816447A patent/CN1337931A/zh active Pending
- 1999-03-08 KR KR1020017011410A patent/KR20010113037A/ko not_active Application Discontinuation
- 1999-03-08 BR BR9917205-4A patent/BR9917205A/pt not_active IP Right Cessation
- 1999-03-08 MX MXPA01009027A patent/MXPA01009027A/es not_active Application Discontinuation
- 1999-03-08 CA CA002366186A patent/CA2366186C/en not_active Expired - Fee Related
- 1999-03-08 WO PCT/EP1999/001467 patent/WO2000053562A1/en not_active Application Discontinuation
- 1999-03-08 DK DK99911748T patent/DK1161410T3/da active
- 1999-03-08 AT AT99911748T patent/ATE266616T1/de not_active IP Right Cessation
- 1999-03-08 JP JP2000604003A patent/JP3752423B2/ja not_active Expired - Fee Related
- 1999-03-08 ES ES99911748T patent/ES2221371T3/es not_active Expired - Lifetime
- 1999-03-08 TR TR2001/02587T patent/TR200102587T2/xx unknown
- 1999-03-08 EP EP99911748A patent/EP1161410B1/de not_active Expired - Lifetime
- 1999-03-08 AU AU30320/99A patent/AU762492B2/en not_active Ceased
- 1999-03-08 DE DE69917332T patent/DE69917332T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1161410B1 (de) | 2004-05-12 |
| WO2000053562A1 (en) | 2000-09-14 |
| AU3032099A (en) | 2000-09-28 |
| JP2002539106A (ja) | 2002-11-19 |
| BR9917205A (pt) | 2001-12-26 |
| DE69917332D1 (de) | 2004-06-17 |
| AU762492B2 (en) | 2003-06-26 |
| CA2366186C (en) | 2007-05-15 |
| CN1337931A (zh) | 2002-02-27 |
| KR20010113037A (ko) | 2001-12-24 |
| DE69917332T2 (de) | 2005-06-16 |
| TR200102587T2 (tr) | 2002-03-21 |
| ES2221371T3 (es) | 2004-12-16 |
| DK1161410T3 (da) | 2004-09-20 |
| EP1161410A1 (de) | 2001-12-12 |
| CA2366186A1 (en) | 2000-09-14 |
| JP3752423B2 (ja) | 2006-03-08 |
| MXPA01009027A (es) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69917332D1 (de) | Retinoid antagonisten und ihre verwendung | |
| WO2006053039A3 (en) | Hydroxybenzoate salts of metanicotine compounds | |
| ES2195943T3 (es) | Compuestos heteroaromaticos biciclicos y triciclicos. | |
| HK1078857A1 (en) | Intermediates for the production of beraprost and its salts | |
| HK1069339A1 (en) | Substituted diketopiperazines as oxytocin antagonists | |
| ATE272398T1 (de) | Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz | |
| IL169257A0 (en) | Cycloalkene dicarboxylic acid compounds as anti-infammatory, immunomodulatory and anti-proliferatory agents | |
| NO20055257L (no) | Ny fremgangsmate for syntesen av s-indolin-2-karboksylsyre og anvendelse derav i syntesen av perindopril | |
| NO20024241L (no) | FremgangsmÕte for fremstilling av citalopram | |
| ZA952614B (en) | The use of carboxylic acid derivatives as drugs | |
| DE3873578D1 (de) | Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| BG99729A (en) | Substituted 6-azaandrostenones | |
| DE60107832D1 (en) | Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe | |
| HUP0401563A2 (hu) | Új piperidinarboxamid-származékok, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| NO20033049D0 (no) | Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1 | |
| AR033987A1 (es) | Compuestos calcioliticos y su uso en la fabricacion de medicamentos | |
| IL132593A0 (en) | Synthesis of acridine derivative multidrug-resistant inhibitors | |
| DE60202969D1 (de) | Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| MY133207A (en) | Substituted benzolactam compaunds | |
| KR19980703883A (ko) | 1-[ω-(3,4-디히드로-2-나프탈레닐)알킬] 환상 아민 유도체,그의 제조 방법 및 이를 함유하는 의약 조성물 | |
| MY136549A (en) | NEW PROCESS FOR THE SYNTHESIS OF (2S, 3aS, 7aS)-PERHYDROINDOLE-2-CARBOXYLIC ACID AND ESTERS THEREOF, AND APPLICATION IN THE SYNTHESIS OF PERINDOPRIL | |
| NO20014889L (no) | Fremgangsmåte for fremstilling av medisinske midler | |
| CA2563575A1 (en) | Enantiomerically pure hexahydropyrrolocyclopentapyridine derivatives | |
| HU9901939D0 (en) | Process for producing a-nor-seco-steroide compounds | |
| JPH07285858A (ja) | 二環性縮合環化合物誘導体およびこれを含有する医薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1161410 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |